CD20 is a 33-37 kDa, non-glycosylated phosphoprotein expressed on the surface of
almost all normal and malignant B cells. It is also the target for rituximab, the most effective
anti-cancer monoclonal antibody developed to date. Rituximab has now been given to over
300,000 lymphoma patients in the last decade and interestingly is now being explored for use
in other disorders, such as autoimmune conditions including rheumatoid arthritis and systemic
lupus erythematosus. Despite the success in immunotherapy, knowledge about the
biology of CD20 is still relatively scarce, partly because it has no known natural ligand and
CD20 knockout mice display an almost normal phenotype. However, interesting insight has
come from work showing that CD20 is resident in lipid raft domains of the plasma membrane
where it probably functions as a store-operated calcium channel following ligation of the
B cell receptor for antigen. In the current review, these and data relating to its activity as a
therapeutic target will be discussed in depth. It is clear that a greater understanding of CD20
biology and the effector mechanisms, such as antibody-dependent cellular cytotoxicity,
complement-dependent cytotoxicity and growth regulation, which operate with anti-CD20
mAb in vivo will allow more efficient exploitation of CD20 as a therapeutic target.
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.